Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS PharmaceuticalCSMYF 93 Return-on-Tangible-Equity is 11.96% as of Feb. 2026, which is 26% below its 10-year median of 16.08. GuruFocus rates CSMYF with a GF Score™ of 93/100 and a GF Value™ of $50.48 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 579 Healthcare Providers & Services companies, COSMOS Pharmaceutical ranks better than 53.37% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. COSMOS Pharmaceutical's annualized net income for the quarter that ended in Feb. 2026 was $209 Mil. COSMOS Pharmaceutical's average shareholder tangible equity for the quarter that ended in Feb. 2026 was $1,746 Mil. Therefore, COSMOS Pharmaceutical's annualized Return-on-Tangible-Equity for the quarter that ended in Feb. 2026 was 11.96%.
The historical rank and industry rank for COSMOS Pharmaceutical's Return-on-Tangible-Equity or its related term are showing as below:
CSMYF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.08 Med: 16.08 Max: 21.6
Current: 11.99
During the past 13 years, COSMOS Pharmaceutical's highest Return-on-Tangible-Equity was 21.60%. The lowest was 11.08%. And the median was 16.08%.
CSMYF's Return-on-Tangible-Equity is ranked better than 53.37% of 579
companies
in the Healthcare Providers & Services industry
Industry Median: 10.21
vs CSMYF: 11.99
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
COSMOS Pharmaceutical Return-on-Tangible-Equity Related Terms
COSMOS Pharmaceutical Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for COSMOS Pharmaceutical's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Feb. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.96% mean?
COSMOS Pharmaceutical (CSMYF) has a Return-on-Tangible-Equity of 11.96% as of Feb. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on COSMOS Pharmaceutical and its competitors. This is 26% below median its historical median of 16.08. Over the past decade, COSMOS Pharmaceutical's Return-on-Tangible-Equity has ranged from 11.08 to 21.60. According to the industry distribution chart, COSMOS Pharmaceutical ranks #270 out of 579 companies in the Healthcare Providers & Services industry, placing it in the top 46.6%.
Is COSMOS Pharmaceutical's Return-on-Tangible-Equity too high?
COSMOS Pharmaceutical's current Return-on-Tangible-Equity of 11.96% is 26% below median its 10-year median of 16.08. Over the past 10 years, this metric has ranged from a low of 11.08 to a high of 21.60. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.21. COSMOS Pharmaceutical's value of 11.96% is 17.1% above this industry median. Based on the distribution chart, COSMOS Pharmaceutical ranks #270 out of 579 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, COSMOS Pharmaceutical has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, COSMOS Pharmaceutical ranks #270 out of 579 companies for Return-on-Tangible-Equity. This puts COSMOS Pharmaceutical in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.21. COSMOS Pharmaceutical's value of 11.96% is 17.1% above this benchmark. Historically, COSMOS Pharmaceutical's own Return-on-Tangible-Equity has ranged from 11.08 to 21.60 over the past decade. While the company's 10-year median is 16.08 vs. the industry median of 10.21, COSMOS Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.21, based on 579 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. COSMOS Pharmaceutical's current Return-on-Tangible-Equity of 11.96% is 17.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on COSMOS Pharmaceutical and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. COSMOS Pharmaceutical's current Return-on-Tangible-Equity is 11.96%, which is 26% below median its own 10-year median of 16.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $50.48, compared to a current price of $37.06 — trading 26.6% below its estimated fair value. The current Return-on-Tangible-Equity is 11.96%, which is 26% below median its 10-year median of 16.08 and 17.1% above the Healthcare Providers & Services industry median of 10.21. COSMOS Pharmaceutical's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current Return-on-Tangible-Equity is 11.96% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 26.6% below its estimated GF Value™ of $50.48.
GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.
Key valuation signals for CSMYF:
Return-on-Tangible-Equity: 11.96% (26% below median its 10-year median of 16.08)
GF Value™: $50.48 vs. price of $37.06 (26.6% below fair value)
Industry Position: 17.1% above the Healthcare Providers & Services median (#270 of 579)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
93GF Score
Get the complete analysis for CSMYF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
